## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($64.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. DexCom Inc Stock Price Live, Charts & News**
- Source: The Economic Times | 20260103T070758 | Neutral | Relevance: 100%
- This article provides a comprehensive overview of DexCom Inc. (DXCM) stock, including live price, charts, and news. It details fundamental data, historical returns, and recent financial statements (Balance Sheet, Income Statement, Cash Flow) up to Q3 2025. The company profile highlights its role in diabetes management with advanced continuous glucose monitoring systems.

**2. Who Owns Dexcom? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260103T000821 | Somewhat-Bullish | Relevance: 100%
- Dexcom, a medical device company focused on continuous glucose monitoring, has seen its stock decline by 14.7% over the last year despite long-term growth expectations. The ownership structure shows significant holdings by passive institutions like Vanguard and BlackRock, with varied activity from active managers and hedge funds. Recent insider transactions are mixed, primarily sales, with some purchases at lower prices, suggesting a nuanced view on short-term valuation but continued long-term confidence.

**3. Abbott unveils new FreeStyle Libre app feature for mealtime decisions**
- Source: MassDevice | 20260105T170153 | Somewhat-Bullish | Relevance: 74%
- Abbott has launched Libre Assist, a new feature within its FreeStyle Libre app designed to help people with diabetes understand how different foods impact their glucose levels. Unlike traditional food logging apps, Libre Assist provides feedback before meals, enabling more informed dietary choices. This new offering was unveiled at CES 2026 and provides a similar functionality to Dexcom's AI-powered meal logging system.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Mizuho | $78 | $75 | +4% |
| 2025-12-11 | Citigroup | $77 | $75 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)
- JPMORGAN CHASE & CO: 3.2% (+101.9%)

### Key Risks

1. Long-term trend broken: trading 8.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.48 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 27.3 |
| Current P/E | 32.8 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 59. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.04% (CS: 54) | Neutral |
| RSI_14 | 59.0 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 0.916x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $67.65
- **Stop Loss:** $64.19 (5.1% risk)
- **Target:** $71.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 249
- **Position Value:** $16,844.85
- **Portfolio %:** 16.84%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*